Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The Ledger
Page 13 of 25 of this archive, newest first.
Page 13
New Zealand caps exenatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
The Journal does not treat a badge as evidence and states so wherever it reports one.
Portugal declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia caps exenatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Arab Emirates caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Chain of custody, and where it begins
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
A tested vial is evidence about a vial
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
What a split-sample exercise can establish, and what it cannot
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Norway caps exenatide prescribing to 12 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Why people actually stop, in the order they actually stop
Why the reason for stopping changes what happens afterwards.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Singapore declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The Netherlands caps exenatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
Switzerland caps semaglutide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.